Frozen plasma aliquots were thawed for ELISA at RT, used once only, with no repeated freeze-thaws allowed, and evaluated immediately. Plasma protein concentration was determined using
Human FABP2/I-FABP DuoSet ELISA (for FABP2), Human Trappin-2/Elafin DuoSet ELISA (for PI3), Human Reg3A DuoSet ELISA Reg3a (for REG3A, all from R&D, Minneapolis, MN, USA), Human Occludin (for OCLN), and KRT15/CK15/Cytokeratin 15 ELISA Kit (for KRT15, both from LSBio, Seattle, WA, USA), and a Human Cytokeratin 20 ELISA Kit (for KRT20, obtained from Novus, Littleton, CO, USA). All ELISA tests were executed according to manufacturer’s instructions. Optimal plasma dilutions were pre-determined in pilot experiments. Plasma samples were diluted for distinct ELISA assays, as follows: Reg3α, both GI and cutaneous aGVHD manifestation group 1:1000, other samples 1:30, PI3 1:100, FABP2 1:1, KRT15 1:300, OCLN 1:10 and KRT20 1:1.
Lupsa N., Szegedi Á., Gézsi A., Vuncs Z., Masszi T., Mikala G., Reményi P., Deola S., Lakshmanan A.P., Terranegra A., Buzás E.I, & Pós Z. (2022). Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement. Biomedicines, 10(3), 519.